News · 26 weeks72+180%
2025-12-282026-06-21
Mix4490d
- Insider24(55%)
- SEC Filings10(23%)
- Other9(20%)
- Earnings1(2%)
Latest news
25 items- INSIDERPresident and CEO Hanna John Walter Jr sold $424,877 worth of shares (17,683 units at $24.03) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 631,959 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Valantine Hannah was granted 9,795 shares and sold $279,728 worth of shares (12,103 units at $23.11) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 36,686 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Cournoyer Christine was granted 9,795 shares, increasing direct ownership by 20% to 58,943 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Riggsbee Richard Bryan was granted 9,795 shares, increasing direct ownership by 33% to 39,312 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Cohen Fred E was granted 9,795 shares, increasing direct ownership by 6% to 165,060 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Gunasekaran Suresh was granted 9,795 shares, increasing direct ownership by 36% to 37,248 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Bickerstaff George was granted 9,795 shares, increasing direct ownership by 7% to 154,061 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERDirector Goldberg Michael was granted 9,795 shares, increasing direct ownership by 5% to 195,737 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- PRCareDx Announces Second KOAR Analysis Published in the Journal of the American Society of NephrologyAlloSure® Kidney elevations are associated with increased risk of graft dysfunction and loss in kidney transplant recipients Data support the role of AlloSure® Kidney as a noninvasive tool for longitudinal risk stratification and clinical decision-making CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the publication of a new analysis from the Kidney Allograft Outcomes AlloSure Registry (KOAR), a landmark multi-center study, in the Journal of the American Society of Ne
- INSIDERPresident and CEO Hanna John Walter Jr sold $528,443 worth of shares (21,998 units at $24.02) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 649,642 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- SECCareDx Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CareDx, Inc. (0001217234) (Filer)
- INSIDERSecretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 1,292 shares, decreasing direct ownership by 1% to 112,632 units (SEC Form 4) (withholding obligation)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERPresident and CEO Hanna John Walter Jr sold $116,045 worth of shares (4,835 units at $24.00) as part of a pre-agreed trading plan, decreasing direct ownership by 0.71% to 671,640 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- SECSEC Form DEFA14A filed by CareDx Inc.DEFA14A - CareDx, Inc. (0001217234) (Filer)
- PRCareDx to Participate in Upcoming Investor ConferencesCareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced the company will participate in the following investor conferences: Jefferies 2026 Global Healthcare Conference at the Marriot Marquis in New York, NY. Presentation on Wednesday, June 3, 2026, at 5:30pm ET. Goldman Sachs 47th Annual Global Healthcare Conference at the Loews Miami Beach Hotel in Miami Beach, FL. Fireside chat on Monday, June 8, 2026, at 1:20pm ET. Live and archived webcasts of the presentations will
- INSIDERDirector Torres Arthur A sold $214,676 worth of shares (10,570 units at $20.31), decreasing direct ownership by 21% to 38,665 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- PRCareDx Announces Dismissal of 2021 Qui Tam SuitCareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the dismissal of a qui tam action filed against the Company. On April 23, 2026, the United States District Court for the Eastern District of New York issued an order dismissing the matter. There is no monetary payment associated with the dismissal. The dismissal order follows the request, by the qui tam plaintiff, for dismissal of the case and the Department of Justice's (DOJ) concurrence in that request. The matter w
- INSIDERSecretary and General Counsel Novack Jeffrey Adam sold $55,581 worth of shares (2,688 units at $20.68) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 113,924 units (SEC Form 4)4 - CareDx, Inc. (0001217234) (Issuer)
- INSIDERSecretary and General Counsel Novack Jeffrey Adam covered exercise/tax liability with 2,873 shares, decreasing direct ownership by 2% to 116,612 units (SEC Form 4) to satisfy withholding obligation4 - CareDx, Inc. (0001217234) (Issuer)
- PRCareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CareDx, Inc. (NASDAQ:CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants. On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restricted stock units (RSUs) for an aggregate of 63,856 shares of common stock. The RSU awards were made pursuant to the Company's 2019 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 2
- SECSEC Form S-3ASR filed by CareDx Inc.S-3ASR - CareDx, Inc. (0001217234) (Filer)
- SECSEC Form 10-Q filed by CareDx Inc.10-Q - CareDx, Inc. (0001217234) (Filer)
- SECCareDx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Regulation FD Disclosure, Entry into a Material Definitive Agreement, Other Events8-K - CareDx, Inc. (0001217234) (Filer)
- PRCareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance TestingTransaction extends CareDx's Precision Medicine Testing Services strategy into specialty oncology with a Medicare-reimbursed commercial-stage MRD test and platform addressing a $4.5 Billion TAM Estimated 2025 Revenue of $34 Million is expected to grow 30-40% annually for the next three years and neutral to CareDx's FY2026 Adjusted EBITDA guidance CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has entered into a definitive agreement to acquire Naveris, a commercial
- PRCareDx Announces First Quarter 2026 Financial ResultsFirst Quarter Revenue Growth of 39% Driven by Strong Performance Across Testing Services and Patient and Digital Solutions Raises 2026 Revenue Guidance to $447 Million to $465 Million and Raises 2026 AEBITDA Guidance to $43 Million to $57 Million CareDx, Inc. (NASDAQ:CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Revenue of $118 million, an increase of 39% year-over-year Testing se
CDNA FAQ
7 questionsWhat does CareDx Inc. do?
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It offers AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; and AlloSure Heart, a dd-cfDNA test to identify underlying cell injury leading to organ rejection. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; Olerup SBT, a product range for sequence-based typing of...Where does CDNA stock trade?
CareDx Inc. (CDNA) is listed on NASDAQ.What sector and industry is CDNA in?
CareDx Inc. operates in the Health Care sector, Medical Specialities industry.When did CareDx Inc. go public?
CareDx Inc. (CDNA) completed its IPO in 2014.What are analysts saying about CDNA?
CareDx Inc. has had 8 recent analyst actions on file. The most recent action was from Craig Hallum: Hold with a $2600.00 price target on 2026-01-06. Recent price targets range from $1000.00 to $4000.00.What companies are similar to CDNA?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare CDNA side-by-side with any of them on Quantisnow.How can I track CDNA on Quantisnow?
Quantisnow aggregates CareDx Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDNA to receive live email and push alerts on every new disclosure.